StockNews.AI
TECH
StockNews.AI
104 days

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

1. Bio-Techne declared a $0.08 quarterly dividend for Q1 2025. 2. A new $500 million share repurchase program has been approved. 3. The repurchase timing is based on share price and market conditions. 4. Bio-Techne achieved approximately $1.2 billion in net sales in fiscal 2024. 5. Forward-looking statements highlight potential market risks impacting performance.

Shares Buyback
+5.68%Current Return
VS
+1.87%S&P 500
$47.7205/07 06:31 AM EDTEvent Start
$50.4305/08 12:26 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Bullish?

Share buybacks typically strengthen stock prices, indicating confidence in financial health. Historical precedents show companies engaging in buybacks often see immediate positive price movements.

How important is it?

Dividends and buybacks typically attract investors, reflecting strong operational health. This increases perceived value in the biotech sector, especially for a stable company like Bio-Techne.

Why Short Term?

The dividend and share repurchase announcements will likely have immediate market reactions. Shareholder sentiments may positively influence price in the near future, typical in similar scenarios.

Related Companies

AMGNILMNAZNREGN
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The share repurchase program may be suspended, amended, or discontinued at any time and does not obligate the Company to acquire any specific dollar amount or number of shares of common stock. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­-techne.com. Forward Looking Statements:Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements. Contact: David Clair, Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416 SOURCE Bio-Techne Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News